

DIGNITANA

Clinically superior scalp cooling

NOVEMBER 16 • 2023



**19% growth and cost reduction
creates another quarter
of positive EBITDA**

Q3 23

QUARTERLY REPORT

19% growth and cost reduction creates another quarter of positive EBITDA

Financial highlights Q3 2023

- Net sales amounted to 22.2 MSEK (18.6), an increase of 19 percent over the same period in 2022.
- Operating result amounted to -3.1 MSEK (-3.6).
- Net result after financial items amounted to -3.7 MSEK (-3.7).
- EBITDA for the Third Quarter is positive at 674 TSEK (-119).
- Earnings per share were -0.05 SEK (-0.06).
- Cash Balance amounted to 7.0 MSEK (6.7).
- Average Daily Treatment Revenue (ADTR)* was 237 TSEK (203), an increase of 17 percent over the same period in 2022.

Business highlights during the period

- Dignitana announced a proposal for Local Coverage Determination of scalp cooling therapy for seven states in the southeastern US.
- Five year follow up results from the DigniCap pivotal trial were published in the Supportive Care in Cancer journal demonstrating both safety and efficacy in the first long term study of scalp cooling.
- Dignitana announced that the partnership with oneservice has expanded to now provide service in the field to DigniCap customers in Europe.
- DigniCap Delta was introduced to customers in Mexico by Celeritas, DigniCap's longtime partner.

”

The foundation of our growth continues to be the extraordinary patient outcomes and customer satisfaction from our superior product."

– Catarina Löwenadler, CEO

Business highlights after the period

- Dignitana announced a sales and marketing partnership with InfuSystem to provide scalp cooling systems in the United States.
- Seven states in the southeastern United States fall under the Local Coverage Determination issued by Palmetto GBA providing coverage for scalp cooling to Medicare recipients as of November 2023.
- Dignitana announced the US Centers for Medicare & Medicaid Services will continue to support scalp cooling however at a reduced average rate beginning January 2024.

Key Figures

DIGNITANA GROUP	Q3 2023	Q3 2022	Q1-Q3 2023	Q1-Q3 2022	FY 2022
Net sales, TSEK	22 219	18 602	64 797	52 750	72 995
Total revenues, TSEK	22 345	21 651	67 109	62 428	83 849
Net profit after financial items, TSEK	-3 685	-3 660	-12 285	-10 400	-22 396
Cash and bank balances, TSEK	6 961	6 737	6 961	6 737	8 869
Earnings per share before and after dilution, SEK	-0,05	-0,06	-0,17	-0,16	-0,34
Average Daily Treatment revenue, TSEK	237	203	240	194	203

* ADTR includes pay-per-treatment revenue from patients and facilities in the U.S. Does not include lease revenue or disposable sales.

DIGNITANA'S VISION IS TO ENSURE THAT CANCER PATIENTS CAN MAINTAIN DIGNITY AND QUALITY OF LIFE DURING AND AFTER CANCER TREATMENT.

19% growth and cost reduction creates another quarter of positive EBITDA

I am pleased to report that Dignitana continues to deliver on the Scale up Strategy with a revenue growth of 19 percent at the same time as decreasing operating expenses with 7 percent Q3 23 over Q3 22, resulting in yet another positive EBITDA quarter. By following our strategic plan and managing costs, we have maintained a stable gross margin while also setting up key initiatives to further accelerate this growth.

The foundation of our growth continues to be the extraordinary patient outcomes and customer satisfaction from our superior product. Our passionate team makes patient care and customer service a priority, and that commitment.

is reflected in the successful results of our patients and the positive experience of our clinical partners, with 94 percent of DigniCap patients who would recommend DigniCap to others and 75 percent of DigniCap patients report a high degree of satisfaction with their DigniCap experience.

As it is still challenging times for health care organizations with worker shortages and high levels of turnover, we have invested in automation and digital portals for patients, health care providers and distributors for optimized workflows and seamless customer experience, which is another key to our high customer satisfaction. Our digital portals, together with our clinical team's diligent work of providing training, have made it possible for us to grow with improved margin in these challenging times. By redeploying devices for optimal utilization, we have created a circular business model good for patient outcome, profitability for customers, and Dignitana, as well as a positive impact on the environment.

US Growth

In the US, our sales and marketing partnership with InfuSystem got off to a solid start in the third period. As the dominant market leader in ambulatory infusion, InfuSystem's strong customer relationships will provide Dignitana with beneficial introductions to new locations while accelerating the sales process.

Reimbursement is progressing well in the US with some DigniCap providers now filing claims and receiving reimbursement. Several more providers are already making the internal changes necessary to switch to our Buy and Bill model in Q4 or early 2024. It is very encouraging that commercial payers are improving in both consistency and level of payments to providers.

Shortly after the period we announced that a Local Coverage Determination will provide Medicare coverage to DigniCap patients in seven states in the southeast. We have already had increased interest from providers in this region to take advantage of this policy change, and it is rewarding to see providers recognizing the positive impact that DigniCap can bring to their practice, both as a draw for new patients and as a revenue-producing therapy. The next step for reimbursement is to transition our CPT codes from Category III to Category I as this will provide an assigned Relative Value Unit to guide payments. In these efforts we continue to work collaboratively with Paxman as a unified voice to the industry, to advance standard of care and provide patients with greater affordability and access.

Global growth

To accelerate growth in Europe and Rest of World we are strengthening partnerships with distributors to extend our reach and make DigniCap available for more patients also in Europe and in prioritized markets outside US. I am confident that these partnerships will accelerate growth in the region, while also decreasing our costs related to that expansion. There is growing interest for DigniCap in South America and Asia, where we are strengthening partnerships with experienced distributors and supporting steady growth in prioritized markets.

Moving forward

As we move into the fourth quarter, we are accelerating growth with emphasis on our key market in the US. We recognize that these are still challenging times, and we appreciate your ongoing support. We continue to build a solid base of customers and infrastructure to provide DigniCap to more patients and work in a cost-efficient manner to achieve profitability and attain the full potential of Dignitana.



Catarina Löwenadler, CEO
Dignitana AB



The Company

Dignitana AB is a medical technology company based in Lund, Sweden and publicly traded on Nasdaq First North Growth Market in Sweden. Company headquarters are in Lund, Sweden and U.S. operations are based in Dallas, Texas. Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Redeye AB is Certified Adviser.

The Company produces The DigniCap Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy to improve well-being and quality of life. The DigniCap Scalp Cooling System was invented in 1999 by a Swedish oncology nurse.

DigniCap has been on the market in Europe since 2001 and has had FDA clearance since 2015 to provide continuous scalp cooling with high efficacy, safety, and acceptable patient comfort. In 2017 Dignitana received expanded clearance from the FDA allowing DigniCap to be used by patients receiving chemotherapy to treat other solid

tumors in addition to the original indication for use by patients with breast cancer. In 2019 Dignitana introduced the next generation DigniCap Delta and the technologically advanced DigniCap Delta model received CE Marking and FDA clearance that year.


Scalp cooling is recognized as standard of care by numerous organizations around the world. European Society for Medical Oncology (ESMO) added scalp cooling as a Category IIB treatment recommendation in 2020 and Cancer Australia added scalp cooling to its Fall 2020 update providing guidance for the management of early breast cancer patients. In the United States clinical recommendations introduced in 2019 and 2020 by the National Comprehensive Cancer Network® and a policy reaffirmation by the American Medical Association in 2022 all contribute to a solid foundation for scalp cooling to become standard of care in the United States.

Business model

The availability of scalp cooling continues to expand as we work toward scalp cooling becoming standard of care providing access to more patients. Dignitana has two business models that each include an ongoing revenue stream from the sale of consumables. In the United States devices are leased to providers and the Company utilizes a pay-per-treatment model. Dignitana offers a buy and bill model that supports reimbursement initiatives. As reimbursement and coverage become more standard, we

will transition providers to this model that is widely used in healthcare.

Outside the U.S. devices are sold to medical facilities and the company also receives revenue from service and maintenance agreements. For global markets that do not have a pay-per-treatment model, the focus is on creating a more sustainable recurring revenue stream from unit sales, lease agreements, service and maintenance fees, and sales of product disposables and supplies.



Reimbursement

Dignitana is committed to ensuring scalp cooling is available to every cancer patient and reimbursement is a critical factor in patient access and affordability. Health care providers are key partners in our efforts to increase accessibility to improve quality of life for as many cancer patients as possible. Dignitana recognizes that providers allocate a range of resources to scalp cooling therapy and their clinical expertise, direct patient care, and skilled operation of the DigniCap device by trained personnel ensure that DigniCap patients have the most successful clinical outcomes possible. The buy and bill model Dignitana offers facilitates a pathway for providers to be reimbursed for the specialized service they are providing to patients.

Since 2021 Dignitana has led the way in reimbursement efforts for scalp cooling in the U.S., including work supporting the introduction of CPT® codes for scalp cooling, a 2022 rate assignment from the Centers for Medicare & Medicaid Services (CMS), and a Local Coverage Determination (LCD) from the Palmetto Medicare Administrative Contractor (MAC) which administers

Medicare benefits in seven states in the southeastern United States. This provides a pathway for successful reimbursement of Medicare claims for patients in the seven-state service area. This is the first such LCD and further advances support for health care providers to receive reimbursement to administer FDA-cleared scalp cooling therapy.

Dignitana continues to work with commercial payers, Medicare and other MACs to advance reimbursement of scalp cooling and improve accessibility and affordability for patients.



The market

The market

DigniCap minimizes chemotherapy-induced hair loss for cancer patients with solid tumors. Globally there are over 17 million incidences of cancer diagnosed annually, with 1.9 million diagnoses occurring in the U.S. each year, and by 2040 the global cancer burden is projected to reach 28 million new incidences solely due to growth and aging of the population. In the U.S. it is estimated that 39 out of 100 women and 40 out of 100 men will develop cancer during their lifetime.

Scalp cooling is primarily used today during the treatment of breast cancer, the most common type of cancer in the world. Globally 2.3 million cases of breast cancer are diagnosed annually, with 291,000 of those in the United States. Scalp cooling is also used by patients with other solid tumors such as ovarian, uterine, endometrial, cervical, and prostate cancers. Non-breast solid tumors represent nearly one million patients in the U.S annually.

Dignitana estimates that up to 60 percent of all cancer patients are on regimens that are compatible with DigniCap. Additionally published studies have found that 8-10 percent of female patients refuse chemotherapy due to concern over hair loss, and 96 percent of potential patients surveyed were interested in scalp cooling.

Market development

The DigniCap Scalp Cooling System is clinically proven to reduce hair loss in cancer patients undergoing chemotherapy for solid tumors. The DigniCap Scalp Cooling System has been marketed worldwide since 2009 and received FDA clearance for the US market in 2015. DigniCap was the first scalp cooling system to receive FDA clearance, with only two other systems now on the market that received clearance more recently.

The DigniCap Delta model was introduced in 2019 and is a smaller, single-patient device providing optimal outcomes and improved ease of use for clinicians and patients. In 2019 DigniCap Delta received CE Marking for Europe and FDA clearance for the U.S., followed by TGA clearance for Australia.

To increase awareness and utilization of scalp cooling Dignitana works with patient advocacy organizations and interest groups in the cancer care community. Dignitana's ongoing sponsorship of Susan G. Komen, the largest breast cancer advocacy group in the world, is an example of this, in addition to numerous partnerships with foundations across the United States.

In most of the world scalp cooling is not a standard option for cancer care. The acceptance, market penetration and utilization of this treatment vary widely, providing significant opportunities for Dignitana all over the world.

Dignitana is committed to advancing the science of scalp cooling by supporting clinical trials and research initiatives among DigniCap users. The Company has initiated several studies that could expand usage to new user groups and show improvements with existing regimens that have exhibited inferior results with scalp cooling previously.



”

Thanks to DigniCap I was able to keep my diagnosis private and continue to work without having to talk about the cancer. I lost about 50% of my hair but even during chemotherapy it was starting to grow again.

I am very thankful for DigniCap!

- Erika

Financial information and comments

DIGNITANA GROUP

Revenues

Group revenues are generated by direct sales of systems, leasing of systems to health care providers, pay-per treatment fees, service and maintenance agreements, sales of individual caps and kit accessories. For the third quarter 2023 net sales amounted to 22,219 TSEK (18,602), an increase over the same period 2022 by 3,617 TSEK representing 19 percent growth.

Dignitana operates by two business models: in the U.S. market DigniCap Delta systems are leased to health care providers and the Company generates revenues from the leasing contracts through monthly leasing fees as well as payment for treatments and sales of products related to patient treatments. Outside the U.S, revenues are generated by sales of DigniCap Delta systems, frequently combined with service and maintenance agreements, as well as the sale of patient-related products and consumables.

The U.S. is still the driver in placing DigniCap Delta on the market using the leasing business model. In the first half of 2023 the Company has continuously focused on reallocating less utilized machines in some facilities to higher usage facilities with increasing demand. This enables the Company to reach more patients with less investment and cost, improve patient outcomes, and thereby achieve higher growth.

Reallocation of devices to optimize utilization will continue as part of normal business operations as the market develops.

Dignitana's revenue and costs comprise of different currencies such as USD, EUR, and SEK. Operational exchange rate balance effects are recognized in the income statement under other operating income and in other operating expenses. In Q3 2023 net exchange rate effects amounted to 125 TSEK (3,337). In Q3 2022 net exchange rate effects were positively affected by revaluation of internal loans in the balance sheet. In Q4 2022 internal loans were redirected from USD to SEK and this will reduce the revaluation effect related to exchange fluctuations in 2023.

Operating Expenses and Operating Result

Operating expenses including Personnel expenses decreased during the quarter compared to the same period last year by 1,014 TSEK and amounted to -14,504 TSEK (-15,518). We have been limiting the use of external consultants during the third quarter and our focus has mainly been on expanding our digital portals and automating internal processes.

Depreciation and amortization in the Group amounted to -3,828 TSEK (-3,504).

The operating result after depreciation for the Group for the third quarter was -3,154 TSEK (-3,623).

Thereby EBITDA for the Third Quarter is positive at 674 TSEK (-119).

Financial net

The financial net was -531 TSEK (-37) in Q3, mainly affected by debt-related interest.

Employees

At the close of the period the Company had 27 (25) employees.

Cash Flow and Financial Position

Consolidated cash flow from operating activities during the quarter was -173 TSEK (-2,092). Total cash flow for the period was 1,563 TSEK (-804). Cash and cash equivalents at the end of the quarter amounted to 5,423 TSEK (7,312).

This includes 5 MSEK in a joint three-year loan from Handelsbanken and Almi Företagspartner that has been taken out in Q3. After the closing of Q3 an asset financing of 415 TUSD from Union Business Leasing, Inc. has been concluded to facilitate capitalized equipment on the US market. The asset financing is related to an existing Master Loan and Security Agreement with UBL.

Board and Management are continuously monitoring the financial position of the Company and are of the opinion that current business plans, in conjunction with various available options for credit facilities, are sufficient financial resources to cover working capital needs for the coming 12-month period.

CAPEX

Capex amounted to 1,045 TSEK (1,351) in the quarter in tangible assets.

The share

Dignitana has been listed on First North Growth Market since November 2011 after having been listed on Spotlight Market in Stockholm since June 2009.

Dignitana AB

TICKER	DIGN
Market Cap September 30	183 MSEK
Number of shareholders, approximately	2,285
Share price September 30	2.59 SEK
Number of shares traded during the quarter	551,690
Number of shares outstanding September 30	70,474,155
Registered share capital	7,047,416 SEK
Par value	0.1 SEK
Certified Adviser	Redeye

Dignitana has only one category of shares, where each share carries one vote and equal rights to the Company's assets and profits. The Company has over time issued new shares and stock option programs and at the general meeting in May 2023 a decision was taken to issue a maximum of 1,800,000 employee warrants to key employees of the Company. The period for the employee stock warrants runs from June 2023 to June 2026.

Largest Shareholders

30 SEPTEMBER 2023	HOLDINGS	PERCENT
AGARTHA AB	20,500,000	29.09%
SWEDBANK ROBUR MICROCAP	5,415,000	7.68%
HANDELSBANKEN MICROCAP SVERIGE	5,247,558	7.45%
AVANZA PENSION	4,719,969	6.70%
CBLDN-UBS FINANCIAL SERVICES INC	4,189,739	5.95%
FÖRSÄKRINGSAKTIEBOLAGET SKANDIA (PUB	2,598,508	3.69%
FE SMÅBOLAG SVERIGE	1,799,900	2.55%
TECHNOVOBIS AB	1,790,593	2.54%
POURSAMAD, AMIR	1,515,349	2.15%
RÜLF, SEMMY	1,015,058	1.44%
TOTAL	48,791,675	69.24%
OTHER SHAREHOLDERS	21,862,480	30.76%
TOTAL	70,474,155	100.00%

Source: Euroclear



” I couldn't be more grateful to DigniCap for saving my hair and keeping me looking like myself through my treatment even when I didn't feel myself.

As a young woman in their 30s, hearing you have cancer is traumatic enough without having to lose that part of yourself."

- Chloe



Risk factors

An investment in securities is associated with risk. Dignitana's activities are affected, and may be affected, by several factors which cannot be completely controlled by the Company. There are risks both in terms of circumstances attributable to Dignitana and those which have no specific connection with the Company.

The non-definitive list of the Company's risks pertains, but is not limited, to: patents, key personnel, growth management, management, restructuring, development costs, competitors, dependence on individual customers, customers, authorization and registration, chemotherapy without side effects, alternative cancer treatment methods, distributors and manufacturers, profitability and future capital requirements, political risk, geopolitical risks, pandemic risks, regulatory or change of laws, disputes and currency risks.

Risks related to COVID-19

The outbreak of COVID-19 in the spring of 2020 has affected the Company's opportunities to reach customers but also customers' ability to offer scalp cooling as a form of treatment. The Company has therefore been impacted financially, although it is not possible to make a full assessment.

Risks related to the Russian invasion of Ukraine

The company's assessment is that the ongoing military conflict in Ukraine should not have any immediate significant effect on the operations. Indirect effects such as increases in energy costs and transportation, increased lead time of components and general cost increases could have some impact on the operations but are deemed as manageable. If the conflict spreads to more territories, this assessment could change. USA is the group's primary market from a sales and supply perspective.

The Board is ultimately responsible for managing and monitoring these risks. Ongoing management is delegated to the CEO, who in turn reports to the Board.

For a detailed explanation of these risk factors view the 2022 Annual Report posted at <https://dignitana.com/investor-relations/financial-reports/>

Other information

Forward-looking statements

This report may contain statements, estimates or projections that constitute "forward-looking statements." Generally, the words "believe", "expect", "intend", "estimate", "anticipate", "project", "will" and similar expressions identify forward-looking statements, which generally are not historical in nature. Forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the Dignitana historical experience or future projects.

Accounting principles

The consolidated financial statements comprise of Dignitana AB and its subsidiaries Dignitana Inc. and Dignitana S.r.l.

This interim report is prepared in accordance with Swedish GAAP, BFNR 2012:1 (K3). The accounting policies remain unchanged compared with the preceding year and are the same principles that were applied for the Annual Report 2022.

Financial statements are presented in SEK, the functional currency of Dignitana AB. Assets and liabilities are translated and presented at the closing rate and the Income statement is translated and presented at period average exchange rates.

For a detailed explanation of accounting principles view the 2022 Annual Report posted at

<https://dignitana.com/investor-relations/financial-reports/>

This Interim Report has not been reviewed by the Group's Auditors

Board assurance

The Board of Directors and Chief Executive Officer declare that this Interim Report provides a fair view of the Company's operations, financial position and results, and describes material risks and uncertainties facing the Company.

Dignitana AB

Corporate Registration Number: 556730-5346

Lund, 16 november 2023

Dignitana AB (publ) Board of Directors

Klas Arildsson
Chairman of the Board

William Cronin
Deputy Chairman of the Board

Lina Karlsson
Board member

Richard Dilorio
Board member

Christian Lindgren
Board member

Ljubo Mrnjavac
Board member

Income Statement – Dignitana Group, TSEK

DIGNITANA GROUP	Q3 2023	Q3 2022	Q1–Q3 2023	Q1–Q3 2022	Full year 2022
Operating Income					
Net sales	22,219	18,602	64,797	52,750	72,995
Capitalized work for own account	0	0	0	0	431
Other operating income	126	3,049	2,312	9,678	10,423
Total Operating Income	22,345	21,651	67,109	62,428	83,849
Operating expense					
Goods for Resale	-7,167	-6,252	-21,088	-17,787	-27,049
Operating expense	-5,402	-6,409	-18,199	-20,556	-28,579
Personnel expense	-8,840	-9,074	-27,294	-23,204	-34,289
Depreciation and amortization of tangible and intangible assets	-3,828	-3,504	-11,257	-10,122	-13,799
Other operating expenses	-262	-35	-580	-446	-747
	-25,499	-25,274	-78,418	-72,115	-104,463
Operating profit (loss)	-3,154	-3,623	-11,309	-9,687	-20,614
Result from financial investments					
Other Interest income and similar items	294	345	877	601	616
Interest expenses and similar items	-825	-382	-1,853	-1,314	-2,398
	-531	-37	-976	-713	-1,782
Profit after financial items	-3,685	-3,660	-12,285	-10,400	-22,396
Profit before tax	-3,685	-3,660	-12,285	-10,400	-22,396
Tax on profit for the period	0	0	0	0	-15
Results for the Period	-3,685	-3,660	-12,285	-10,400	-22,411
Average number of shares before and after dilution	70,474,155	65,059,155	70,474,155	65,059,155	66,130,254
Earnings per share before and after dilution, SEK	-0.05	-0.06	-0.17	-0.16	-0.34

Balance Sheet – Dignitana Group, TSEK

DIGNITANA GROUP	2023-09-30 2023	2022-09-30 2022	2022-12-31 2022
ASSETS			
FIXED ASSETS			
Intangible assets			
Capitalized expenses for development	3,723	7,841	7,139
	3,723	7,841	7,139
Tangible assets			
Equipment, tools and installations	173	273	164
Machinery and other technical facilities	42	59	54
Leasing machines	22,878	30,575	26,952
	23,093	30,907	27,170
Financial assets			
Other long term receivables	350	0	175
	350	0	175
Total Fixed Assets	27,166	38,748	34,484
CURRENT ASSETS			
Inventories and similar			
Finished goods and goods for resale	5,538	8,078	5,053
	5,538	8,078	5,053
Current Receivables			
Accounts Receivable	5,375	7,431	6,505
Current Tax Assets	0	106	0
Other Current Receivables	552	588	756
Prepaid expenses and accrued income	2,779	2,440	2,884
	8,706	10,565	10,145
Cash and Bank Balances	6,961	6,737	8,869
Total Current Assets	21,205	25,380	24,067
Total Assets	48,371	64,128	58,551
EQUITY AND LIABILITIES			
Equity			
Share Capital	7,047	6,506	7,047
Unregistered share capital	0	0	0
Ongoing new issue	0	0	0
Other contributed capital	246,550	222,989	245,866
Other equity including profit for the year	-240,542	-216,750	-228,663
Total Equity	13,055	12,745	24,250
Provisions			
Other provisions	350	6	187
	350	6	187
Long Term Liabilities			
Other long term liabilities	7,464	11,824	8,614
Total Long Term Liabilities	7,464	11,824	8,614
Current Liabilities			
Liabilities to credit institutions	11,728	10,097	9,653
Accounts payable	3,165	7,349	5,575
Other current liabilities	6,400	11,151	1,909
Accrued expenses and deferred income	6,209	10,956	8,363
Total current liabilities	27,502	39,553	25,500
Total liabilities	34,966	51,377	34,114
Total Equity and Liabilities	48,371	64,128	58,551

Consolidated Statement of Changes in Equity

– Dignitana Group, TSEK

DIGNITANA GROUP	Share capital	Other contributed capital	Retained earnings, incl. net loss for the year	Total equity
Opening equity on 1/1/2022	6,506	222,692	-198,012	31,186
Net loss for the period			-10,400	-10,400
Share warrants		378		378
Option program 2022			720	720
Issue costs		-81		
Change in translation difference relating to subsidiaries			-9,058	-9,058
Closing equity on 9/30/2022	6,506	222,989	-216,750	12,745
Net loss for the period			-12,011	-12,011
Share warrants				0
Option program 2022			240	240
New share issue	541	24,314		24,854
Issue costs		-1,437		-1,437
Change in translation difference relating to subsidiaries			-143	-143
Closing equity on 12/31/2022	7,047	245,866	-228,663	24,250
Net loss for the period			-12,285	-12,285
Share warrants		684		684
Change in translation difference relating to subsidiaries			406	406
Closing equity on 9/30/2023	7,047	246,550	-240,542	13,055

Statement of Cash Flows – Dignitana Group, TSEK

DIGNITANA GROUP	Q3 2023	Q3 2022	Q1–Q3 2023	Q1–Q3 2022	Full year 2022
Operating activities					
Profit after financial investments	-3,685	-3,660	-12,285	-10,400	-22,396
Adjustments for items not affecting cash flows, etc	3,526	125	11,817	888	6,178
Tax paid	0	-18	-16	-42	-59
Cash flow from operating activities before changes in working capital	-159	-3,553	-484	-9,554	-16,277
Cash flow from changes in working capital					
Change in inventories	-573	-838	-1,370	-492	813
Change in other current receivables	1,263	2,238	1,536	-1,091	-1,684
Change in other current liabilities	-704	61	-4,961	458	-1,016
Cash flows from operating activities	-173	-2,092	-5,279	-10,679	-18,164
Investing activities					
Investments in intangible assets	0	0	0	0	-431
Investments in tangible assets	-1,045	-1,351	-3,139	-1,823	-2,790
Proceeds from sale of tangible assets	593	0	593	0	91
Investments in other financial fixed assets	-58	0	-175	0	0
Cash flows from investing activities	-510	-1,351	-2,721	-1,823	-3,130
Financing activities					
New share issue	0	0	0	0	24,855
Issue expenses	0	-81	0	-81	-1,518
Options issued	0	0	684	378	378
New loans	0	5,204	5,000	10,204	10,000
Repaid loans	0	0	0	0	-10,000
Changes in long and short term liabilities to credit institutions	2,246	-2,484	332	-6,523	-8,685
Cash flow from financial activities	2,246	2,639	6,016	3,978	15,030
Cash flow for the period	1,563	-804	-1,984	-8,524	-6,264
Cash and cash equivalents at beginning of period					
Cash and cash equivalents at beginning of period	5,423	7,312	8,869	14,501	14,501
Exchange-rate differences in cash and cash equivalents					
Exchange-rate differences in cash and cash equivalents	-25	229	76	760	632
Cash and cash equivalents at end of period	6,961	6,737	6,961	6,737	8,869

Income Statement – Dignitana AB, TSEK

DIGNITANA AB, PARENT COMPANY	Q3 2023	Q3 2022	Q1–Q3 2023	Q1–Q3 2022	Full year 2022
Operating Income					
Net sales	3,384	2,537	10,943	8,351	12,140
Capitalized work for own account	0	0	0	0	431
Other operating income	125	3,003	2,242	9,394	9,453
Total Operating Income	3,509	5,540	13,185	17,745	22,024
Operating expense					
Goods for Resale	-167	-518	-2,201	-2,714	-5,911
Operating expense	-1,966	-1,699	-6,142	-8,008	-21,666
Personnel expense	-3,651	-2,920	-12,212	-6,061	-10,242
Depreciation and amortization of tangible and intangible assets	-1,154	-1,130	-3,462	-5,515	-6,659
Other operating expenses	-262	-97	-579	-272	-431
	-7,200	-6,364	-24,596	-22,570	-44,909
Operating profit (loss)	-3,691	-824	-11,411	-4,825	-22,885
Result from financial investments					
Other Interest income and similar items	293	345	876	601	992
Interest expenses and similar items	-521	40	-866	-16	-712
	-228	385	10	585	280
Profit after financial items	-3,919	-439	-11,401	-4,240	-22,605
Profit before tax	-3,919	-439	-11,401	-4,240	-22,605
Results for the Period	-3,919	-439	-11,401	-4,240	-22,605

Balance Sheet – Dignitana AB, TSEK

DIGNITANA AB, PARENT COMPANY	2023-09-30	2022-09-30	2022-12-31
ASSETS			
FIXED ASSETS			
Intangible assets			
Capitalized expenses for development	3,702	7,815	7,116
	3,702	7,815	7,116
Tangible assets			
Equipment, tools and installations	46	0	0
Other machinery and other technical facilities	42	59	54
Leasing machines	31	68	59
	119	127	113
Financial assets			
Participations in group companies	66,198	66,198	66,198
Receivable from group companies	8,944	7,230	10,698
Other long term receivables	350	0	175
	75,492	73,428	77,071
Total Fixed Assets	79,313	81,370	84,300
CURRENT ASSETS			
Inventories and similar			
Finished goods and goods for resale	2,339	5,320	2,766
	2,339	5,320	2,766
Current Receivables			
Accounts Receivable	1,074	1,367	1,470
Receivables from group companies	1,593	1,534	0
Current Tax Assets	0	106	0
Other Current Receivables	360	449	667
Prepaid expenses and accrued income	699	503	446
	3,726	3,959	2,583
Cash and Bank Balances	2,237	3,212	5,455
Total Current Assets	8,302	12,491	10,804
Total Assets	87,615	93,861	95,104

Balance Sheet – Dignitana AB, TSEK

DIGNITANA AB, PARENT COMPANY	2023-09-30	2022-09-30	2022-12-31
EQUITY AND LIABILITIES			
Equity			
Restricted equity			
Share Capital	7,047	6,506	7,047
Fund for development expenses	3,702	7,816	7,116
	10,749	14,322	14,163
Non-restricted equity			
Share premium reserves	246,550	222,989	245,866
Other non-restricted equity	-175,261	-156,770	-156,070
Results for the period	-11,401	-4,240	-22,605
	59,888	61,979	67,191
Total Equity	70,637	76,301	81,354
Provisions			
Other provisions	350	0	175
	350	0	175
Long Term Liabilities			
Other long term liabilities	5,000	0	0
Total Long Term Liabilities	5,000	0	0
Current Liabilities			
Accounts payable	809	1,025	921
Current payable to group company	636	361	6,592
Other current liabilities	6,034	10,716	1,345
Accrued expenses and deferred income	4,149	5,458	4,717
Total current liabilities	11,628	17,560	13,575
Total liabilities	11,628	17,560	13,575
Total Equity and Liabilities	87,615	93,861	95,104

Financial calendar

15 Feb 2024	2023 Year End Report
2 May 2024	2023 Annual Report
23 May 2024	Q1 Report
23 May 2024	Annual General Meeting
22 August 2024	Q2 Report
21 Nov 2024	Q3 Report
20 Feb 2025	2024 Year End Report

All financial reports are available at
www.dignitana.com/investor-relations/financial-reports/

Contact information

Dignitana AB

Traktorgränden 3, 226 60 Lund
+46 (0) 46-16 30 90
info@dignitana.com
investorrelations@dignitana.com
www.dignitana.com

Certified Adviser

Redeye AB
+46 8 121 576 90
certifiedadviser@redeye.se
www.redeye.se